These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

821 related articles for article (PubMed ID: 29055843)

  • 1. Revisiting the definition of dose-limiting toxicities in paediatric oncology phase I clinical trials: An analysis from the Innovative Therapies for Children with Cancer Consortium.
    Bautista F; Moreno L; Marshall L; Pearson ADJ; Geoerger B; Paoletti X
    Eur J Cancer; 2017 Nov; 86():275-284. PubMed ID: 29055843
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Towards new methods for the determination of dose limiting toxicities and the assessment of the recommended dose for further studies of molecularly targeted agents--dose-Limiting Toxicity and Toxicity Assessment Recommendation Group for Early Trials of Targeted therapies, an European Organisation for Research and Treatment of Cancer-led study.
    Postel-Vinay S; Collette L; Paoletti X; Rizzo E; Massard C; Olmos D; Fowst C; Levy B; Mancini P; Lacombe D; Ivy P; Seymour L; Le Tourneau C; Siu LL; Kaye SB; Verweij J; Soria JC
    Eur J Cancer; 2014 Aug; 50(12):2040-9. PubMed ID: 24880774
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Towards using a full spectrum of early clinical trial data: a retrospective analysis to compare potential longitudinal categorical models for molecular targeted therapies in oncology.
    Colin P; Micallef S; Delattre M; Mancini P; Parent E
    Stat Med; 2015 Sep; 34(22):2999-3016. PubMed ID: 26059319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heterogeneity in the definition of dose-limiting toxicity in phase I cancer clinical trials of molecularly targeted agents: a review of the literature.
    Le Tourneau C; Razak AR; Gan HK; Pop S; Diéras V; Tresca P; Paoletti X
    Eur J Cancer; 2011 Jul; 47(10):1468-75. PubMed ID: 21482105
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Case Example of Dose Optimization Using Data From Bortezomib Dose-Finding Clinical Trials.
    Lee SM; Backenroth D; Cheung YK; Hershman DL; Vulih D; Anderson B; Ivy P; Minasian L
    J Clin Oncol; 2016 Apr; 34(12):1395-401. PubMed ID: 26926682
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical trial simulations in paediatric oncology: A feasibility study from the Innovative Therapies for Children with Cancer Consortium.
    Janssen JM; Zwaan CM; Schellens JHM; Beijnen JH; Huitema ADR
    Eur J Cancer; 2017 Nov; 85():78-85. PubMed ID: 28892776
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Determinants of the recommended phase 2 dose of molecular targeted agents.
    Hansen AR; Cook N; Amir E; Siu LL; Abdul Razak AR
    Cancer; 2017 Apr; 123(8):1409-1415. PubMed ID: 28182250
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The performance of model-based versus rule-based phase I clinical trials in oncology : A quantitative comparison of the performance of model-based versus rule-based phase I trials with molecularly targeted anticancer drugs over the last 2 years.
    van Brummelen EM; Huitema AD; van Werkhoven E; Beijnen JH; Schellens JH
    J Pharmacokinet Pharmacodyn; 2016 Jun; 43(3):235-42. PubMed ID: 26960536
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparative analysis of paediatric dose-finding trials of molecularly targeted agent with adults' trials.
    Paoletti X; Geoerger B; Doz F; Baruchel A; Lokiec F; Le Tourneau C
    Eur J Cancer; 2013 Jul; 49(10):2392-402. PubMed ID: 23540589
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Methodologic guidelines for the design of high-dose chemotherapy regimens.
    Margolin K; Synold T; Longmate J; Doroshow JH
    Biol Blood Marrow Transplant; 2001; 7(8):414-32. PubMed ID: 11569887
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Untenable dosing: A common pitfall of modern DLT-targeting Phase I designs in oncology.
    Frankel PH; Chung V; Xing Y; Longmate J; Groshen S; Newman EM
    Curr Probl Cancer; 2020 Dec; 44(6):100583. PubMed ID: 32446637
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Defining dose-limiting toxicity for phase 1 trials of molecularly targeted agents: results of a DLT-TARGETT international survey.
    Paoletti X; Le Tourneau C; Verweij J; Siu LL; Seymour L; Postel-Vinay S; Collette L; Rizzo E; Ivy P; Olmos D; Massard C; Lacombe D; Kaye SB; Soria JC
    Eur J Cancer; 2014 Aug; 50(12):2050-6. PubMed ID: 24928189
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship Between Response and Dose in Published, Contemporary Phase I Oncology Trials.
    Hazim A; Mills G; Prasad V; Haslam A; Chen EY
    J Natl Compr Canc Netw; 2020 Apr; 18(4):428-433. PubMed ID: 32259790
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reporting and impact of subsequent cycle toxicities in oncology phase I clinical trials.
    Rami A; DuBois SG; Campbell K
    Clin Trials; 2024 Apr; 21(2):211-219. PubMed ID: 37961910
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase 1 study of eribulin mesylate (E7389), a novel microtubule-targeting chemotherapeutic agent, in children with refractory or recurrent solid tumors: A Children's Oncology Group Phase 1 Consortium study (ADVL1314).
    Schafer ES; Rau RE; Berg S; Liu X; Minard CG; D'Adamo D; Scott R; Reyderman L; Martinez G; Devarajan S; Reid JM; Fox E; Weigel BJ; Blaney SM
    Pediatr Blood Cancer; 2018 Aug; 65(8):e27066. PubMed ID: 29719113
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of age on dose-limiting toxicities in phase I dose-escalation trials.
    Schwandt A; Harris PJ; Hunsberger S; Deleporte A; Smith GL; Vulih D; Anderson BD; Ivy SP
    Clin Cancer Res; 2014 Sep; 20(18):4768-75. PubMed ID: 25028396
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cumulative Toxicity in Targeted Therapies: What to Expect at the Recommended Phase II Dose.
    Altzerinakou MA; Collette L; Paoletti X
    J Natl Cancer Inst; 2019 Nov; 111(11):1179-1185. PubMed ID: 30838405
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trends in the characteristics, dose-limiting toxicities and efficacy of phase I oncology trials: The Cancer Research UK experience.
    Wong HH; Barton C; Acton G; McLeod R; Halford S
    Eur J Cancer; 2016 Oct; 66():9-16. PubMed ID: 27514008
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety, pharmacokinetic, and pharmacodynamic phase I dose-escalation trial of PF-00562271, an inhibitor of focal adhesion kinase, in advanced solid tumors.
    Infante JR; Camidge DR; Mileshkin LR; Chen EX; Hicks RJ; Rischin D; Fingert H; Pierce KJ; Xu H; Roberts WG; Shreeve SM; Burris HA; Siu LL
    J Clin Oncol; 2012 May; 30(13):1527-33. PubMed ID: 22454420
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adaptive dose finding for phase I clinical trials of drugs used for chemotherapy of cancer.
    Potter DM
    Stat Med; 2002 Jul; 21(13):1805-23. PubMed ID: 12111891
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.